GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PolyPid Ltd (NAS:PYPD) » Definitions » Capex-to-Operating-Income

PolyPid (PolyPid) Capex-to-Operating-Income : 0.00 (As of Dec. 2023)


View and export this data going back to 2020. Start your Free Trial

What is PolyPid Capex-to-Operating-Income?

Capex-to-Operating-Income measures a company's investments in physical assets such as property, industrial buildings or equipment to its operating income.

PolyPid's Capital Expenditure for the three months ended in Dec. 2023 was $0.00 Mil. Its Operating Income for the three months ended in Dec. 2023 was $-6.00 Mil.

GuruFocus do not calculate Capex-to-Operating-Income if the Operating Income is negative.


PolyPid Capex-to-Operating-Income Historical Data

The historical data trend for PolyPid's Capex-to-Operating-Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PolyPid Capex-to-Operating-Income Chart

PolyPid Annual Data
Trend Dec12 Dec13 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Capex-to-Operating-Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

PolyPid Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Capex-to-Operating-Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of PolyPid's Capex-to-Operating-Income

For the Biotechnology subindustry, PolyPid's Capex-to-Operating-Income, along with its competitors' market caps and Capex-to-Operating-Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PolyPid's Capex-to-Operating-Income Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, PolyPid's Capex-to-Operating-Income distribution charts can be found below:

* The bar in red indicates where PolyPid's Capex-to-Operating-Income falls into.



PolyPid Capex-to-Operating-Income Calculation

PolyPid's Capex-to-Operating-Income for the fiscal year that ended in Dec. 2023 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (-0.196) / -22.867
=N/A

PolyPid's Capex-to-Operating-Income for the quarter that ended in Dec. 2023 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (0) / -5.999
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


PolyPid  (NAS:PYPD) Capex-to-Operating-Income Explanation

Capex-to-Operating-Income assesses how much emphasis a company is placing upon investing in capital-intensive projects. The ratio is generally a good gauge to quantify how much focus on growth a company has. Typically, smaller companies that are still growing and expanding will have a higher Capex to Operating Income Ratio, since such businesses are likely investing more in physical assets. Lower ratios could indicate that a company has reached maturity and it is no longer pursuing aggressive growth.


PolyPid Capex-to-Operating-Income Related Terms

Thank you for viewing the detailed overview of PolyPid's Capex-to-Operating-Income provided by GuruFocus.com. Please click on the following links to see related term pages.


PolyPid (PolyPid) Business Description

Industry
Traded in Other Exchanges
N/A
Address
18 Hasivim Street, P.O Box 7126, Petach Tikva, ISR, 495376
PolyPid Ltd is a clinical-stage biopharmaceutical company engaged in the research and development of products based on PLEX (Polymer-Lipid Encapsulation MatriX), the company's proprietary drug delivery technology. PLEX is capable of encapsulating many types of drugs to enable targeted, localized drug delivery into the body over extended periods of time with pre-determined release rates thus optimizing drug treatment regimens. BonyPid, PolyPid, Opzifend, Ssisurg, Elyfssi, and Bacyssio are trademarks of the company. The company is subject to extensive regulation by the FDA, under the Federal Food, Drug, and Cosmetic Act, as well as by other federal, state, and local regulatory agencies.